辉瑞公司在2025年AACR年会上展示了其合作伙伴Nona生物科学的针对MSLN的TOP1i ADC的临床前数据-动脉网

Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1iased ADC Targeting MSLN at AACR Annual Meeting 2025

CISION 等信源发布 2025-04-28 08:00



可切换为仅中文







CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

April 27, 2025

2025年4月27日

/PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from 'Idea to IND' (I to I

/PRNewswire/ -- 诺纳生物，一家提供从“概念到新药临床试验申请”（I to I）一体化解决方案的全球生物技术公司

商标

), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisomerase 1 inhibitor (TOP1i)-based antibody-drug conjugate (ADC) targeting mesothelin (MSLN), at the AACR Annual Meeting 2025. This ADC was originally developed using Nona Biosciences' proprietary Harbour Mice.

），今天宣布其合作伙伴辉瑞公司在2025年AACR年会上展示了PF-08052666（HBM9033；SGN-MesoC2）的临床前数据，这是一种首创的基于拓扑异构酶1抑制剂（TOP1i）的抗体药物偶联物（ADC），靶向间皮素（MSLN）。该ADC最初是使用诺纳生物公司的专有Harbour Mice开发的。

and integrated ADC platforms. Pfizer acquired its global clinical development and commercialization rights on

和集成的ADC平台。辉瑞获得了其全球临床开发和商业化权利

December 14, 2023

2023年12月14日

。

Poster Presentation at AACR Annual Meeting 2025

2025年AACR年会海报展示

Title:

标题：

PF-08052666 (HBM9033), a first-in-class topoisomerase 1 inhibitor-based ADC targeting MSLN, demonstrates potent antitumor activity in preclinical models of ovarian, lung, and colorectal cancers

PF-08052666（HBM9033）是一种首创的基于拓扑异构酶1抑制剂的ADC，靶向MSLN，在卵巢癌、肺癌和结直肠癌的临床前模型中显示出强大的抗肿瘤活性。

Abstract Number:

摘要编号：

324

Poster Board Number:

海报板编号：

Session Title:

会议标题：

Antireceptors and Other Biological Therapeutic Agents

抗受体及其他生物治疗剂

Session Date:

会话日期：

April 27, 2025

2025年4月27日

PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker-payload, and a higher drug-to-antibody ratio (DAR). It consists of a human IgG1 monoclonal antibody conjugated to a potent camptothecin-based TOP1i payload with a protease-cleavable linker, achieving an average DAR of 8..

PF-08052666 旨在通过一种新型抗体、差异化的连接子-载荷以及更高的药物抗体比 (DAR) 来克服早期抗 MSLN ADC 的局限性。它由一种人源 IgG1 单克隆抗体组成，该抗体通过蛋白酶可切割的连接子与强效的基于喜树碱的 TOP1i 载荷结合，平均 DAR 达到 8。

Key Preclinical Findings Presented at AACR Annual Meeting 2025

2025年AACR年会展示的关键临床前研究结果

In vitro

体外

, PF-08052666 demonstrated direct cytotoxicity through delivery of payload to MSLN-positive cells, bystander killing activity on co-cultured MSLN-negative cells, and maintained cytotoxicity even in the presence of physiologically relevant concentrations of soluble MSLN.

，PF-08052666通过将有效载荷递送至MSLN阳性细胞展现出直接的细胞毒性，对共培养的MSLN阴性细胞具有旁观者杀伤活性，并且即使在生理相关浓度的可溶性MSLN存在下仍保持细胞毒性。

In vivo

在体内

, PF-08052666 outperformed a DM4-based anti-MSLN benchmark ADC in both cell-line and patient-derived xenograft models across multiple tumor types, including ovarian, lung, and colorectal cancers.

，PF-08052666 在多种肿瘤类型（包括卵巢癌、肺癌和结直肠癌）的细胞系和患者来源的异种移植模型中均优于基于 DM4 的抗 MSLN 基准 ADC。

PF-08052666 also outperformed the DM4-based anti-MSLN benchmark ADC in heterogeneous xenograft models consisting of ad-mixed MSLN-positive and MSLN-negative cells, demonstrating the increased bystander activity of the novel linker-payload of MesoC2.

PF-08052666 在由混合的 MSLN 阳性和 MSLN 阴性细胞组成的异质性异种移植模型中，也优于基于 DM4 的抗 MSLN 基准 ADC，展示了 MesoC2 新型连接子-有效载荷增强的旁观者活性。

These promising preclinical results support the ongoing first-in-human phase 1 clinical trial of PF-08052666 in patients with advanced solid tumors (

这些令人鼓舞的临床前结果支持了PF-08052666在晚期实体瘤患者中进行的首次人体1期临床试验的继续进行 (

NCT06466187

), which is currently enrolling participants.

），目前正在招募参与者。

'The preclinical data on PF-08052666 presented by Pfizer at AACR 2025 reflects the strength of our technology platforms and our dedication to advancing transformative therapies,' said

“辉瑞在2025年AACR上展示的PF-08052666的临床前数据反映了我们技术平台的实力以及我们致力于推进变革性疗法的决心，”

Jingsong Wang

王京松

, MD, PhD, Chairman of Nona Biosciences. 'By leveraging our industry-leading technology platforms, we continue to drive innovation that enables the development of next-generation biotherapeutics. We look forward to further collaboration with Pfizer to accelerate breakthroughs that address critical medical needs.'.

医学博士，非那生物科学公司董事长。“通过利用我们行业领先的技术平台，我们不断推动创新，使下一代生物治疗药物的开发成为可能。我们期待与辉瑞进一步合作，加速满足关键医疗需求的突破。”

About PF-08052666 (HBM9033)

关于PF-08052666（HBM9033）

PF-08052666 is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in PF-08052666 is derived from the Harbour Mice

PF-08052666是一种靶向人类MSLN的ADC药物，MSLN是一种在多种实体瘤中上调的肿瘤相关抗原（TAA）。PF-08052666中的全人源单克隆抗体（mAb）源自Harbour Mice。

platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning PF-08052666 as a potential globally best-in-class therapeutic option..

该平台具有经过良好调整的特性，表现出与可溶性MSLN的结合减少，同时保持对膜结合型MSLN的强大结合和内化能力。单克隆抗体的独特设计旨在增强在不同MSLN表达水平的各种临床前肿瘤模型中的效力，使PF-08052666成为潜在的全球最佳治疗选择。

About Nona Biosciences

关于诺纳生物

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from 'Idea to IND' (I to I

诺纳生物是一家全球生物技术公司，致力于前沿技术创新，并提供从“概念到新药临床试验申请”（Idea to IND）的一体化解决方案。

商标

), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice.

），涵盖从靶点验证、抗体发现到临床前研究的全过程。一体化的抗体及相关发现服务包括多种模式，从抗原制备、动物免疫、单个B细胞筛选到抗体先导物的生成与工程改造、可开发性评估及药理学评价，充分利用Harbour Mice的优势。

platforms and the experienced therapeutic antibody discovery team.

平台以及经验丰富的治疗性抗体发现团队。

Harbour Mice

港口老鼠

generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice

生成完全人源的单克隆抗体，采用经典的两条轻链和两条重链（H2L2）格式以及仅重链（HCAb）格式。整合 Harbour Mice 技术。

and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:

并且凭借一个B细胞克隆平台，九诺生物科学公司专注于推动全球范围内变革性下一代药物的发明。欲了解更多信息，请访问：

www.nonabio.com

。

SOURCE Nona Biosciences

来源：九诺生物科学

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &